Advanced Search

 

Study ID Status Title Patient Level Data
GLP107865 Completed Clinical assessment of GSK716155 for Type 2 Diabetes Mellitus -A Phase I/II study to investigate the safety, pharmacokinetics and pharmacodynamics of GSK716155 in Japanese subjects with type 2 diabetes mellitus Study Listed on ClinicalStudyDataRequest.com
GLP110125 Completed A 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of GSK716155, with Byetta as an Open Label Active Reference, in Subjects with Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
GRZ107460 Completed A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK364735 Monotherapy Versus Placebo Over 10 days in HIV-1 Infected Adults.
GRZ108532 Completed A Single Dose, Randomized, 5-Period, Balanced, Crossover Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK364735 and Pharmacokinetics Following a Double Blind, Placebo Controlled, Repeat Dose Administration to Healthy Subjects.
GT1109727 Completed Single-Blind, randomised, placebo-controlled first time in human study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of single oral escalating doses of GSK1018921 in healty volunteers and a randomized, double-blind, double dummy, placebo controlled, three-way crossover study in a separate cohort of healthy volunteers to test the effect of single doses of GSK1018921 and nicotine on qEEG and MMN in healthy volunteers
GW679769/903 Completed A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of GW679769 (30mg and 90mg) on Sleep Continuity, PSG Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Subjects with Primary Insomnia
GW679769/904 Completed An exploratory study to investigate the effects of the NK1 antagonist GW679769, 60 mg once daily for 4 days, on gastric accommodation, gastric emptying and gastric distension-induced perception and discomfort in adult male and female patients with functional dyspepsia, in a single center, placebo-controlled, double-blind, randomised, two-period crossover study
H3A106104 Terminated An Open Label, Dose Escalation Study With A Double Blind Randomised Placebo Controlled Withdrawal To Examine The Effects Of The Histamine H3 Antagonist GSK189254 In Patients With Narcolepsy.
H3A106308 Completed A double-blind, double-dummy, placebo-controlled, incomplete block, two period crossover study of the histamine H3 antagonist GSK189254 and duloxetine in the electrical hyperalgesia model of central sensitisation in healthy volunteers
H3B106026 Completed A PET study using [11C] GSK189254 to establish the dose, plasma concentration and brain receptor occupancy relationship of GSK239512, a histamine H3 antagonist, in healthy subjects
H3B109689 Completed A single blind, placebo-controlled, randomised study in mild to moderate Alzheimer’s disease patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK239512, a selective histamine H3 receptor antagonist Study Listed on ClinicalStudyDataRequest.com
HGS1006-C1056 Completed A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) Study Listed on ClinicalStudyDataRequest.com
HGS1006-C1057 Completed A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Study Listed on ClinicalStudyDataRequest.com
HGS1021-C1063 Completed A randomized, single-blind, placebo-controlled study to evaluate the safety and tolerability of raxibacumab (human monoclonal antibody to B. anthracis protective antigen) in healthy subjects Study Listed on ClinicalStudyDataRequest.com
HGS1021-C1069 Completed An Open-Label Study to Evaluate the Immunogenicity and Safety of Raxibacumab (Human Monoclonal Antibody to B. anthracis Protective Antigen) Administered in Healthy Subjects Study Listed on ClinicalStudyDataRequest.com
HH3104994 Completed A randomised, double blind, placebo controlled, two way crossover, three phase study to investigate the trial models; Vienna Challenge Chamber, in and out of season and Park study in season and the clinical efficacy of repeat doses of fluticasone propionate in subjects with seasonal allergic rhinitis (SAR).
HH3110161 Completed A double-blind, placebo-controlled, randomized cross-over single dose escalation study and a double-blind, placebo-controlled, randomised parallel group 7-days once daily repeat dose study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of oral H1/H3 dual antagonist compound in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
HHI110157 Completed A double-blind, placebo-controlled, randomized single dose escalation study and a double-blind, placebo-controlled, randomised parallel group 14-days once daily repeat dose study to investigate safety, tolerability and pharmacokinetics of an intranasal H1/H3 dual antagonist compound in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
HMA110015 Completed A Two-Part Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Oral Doses of GSK256073A, in a Randomized, Single-Blind, Dose Escalation study in Healthy Adult Subjects
HMA110541 Completed A Second Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single and a Repeat Oral Dose of GSK256073A in Healthy Adult Subjects
HMA111316 Completed A Study to Evaluate the Ability of the HM74A agonist GSK256073A to Block Niacin-induced Flushing in Healthy Adult Subjects
HPR10006 Completed A pilot, phase II, open-label, single arm study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of GW640385 when administered with ritonavir in combination with NRTIs for 48 weeks in HIV-1 infected adults
HPR20001 Terminated Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/ritonavir Compared to Open-label Current PI therapy in HIV-1 infected, Protease Inhibitor Experienced Adults for 2 weeks with Long-term Assessment (>48 weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
HPV-Meta-analysis-201110 Completed Integrated Safety Summary of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix®)
HS2100275 Completed An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.